Ledipasvir; Sofosbuvir Patent Expiration
Ledipasvir; Sofosbuvir is Used for treating chronic Hepatitis C virus (HCV) infection in treatment-naive genotype 1 patients for an 8-week duration. It was first introduced by Gilead Sciences Inc
Ledipasvir; Sofosbuvir Patents
Given below is the list of patents protecting Ledipasvir; Sofosbuvir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Harvoni | US10039779 | Combination formulation of two antiviral compounds | Jan 30, 2034 | Gilead Sciences Inc |
| Harvoni |
US10039779 (Pediatric) | Combination formulation of two antiviral compounds | Jul 30, 2034 | Gilead Sciences Inc |
| Harvoni | US10456414 | Methods for treating HCV | Sep 14, 2032 | Gilead Sciences Inc |
| Harvoni | US7964580 | NA | Mar 26, 2029 | Gilead Sciences Inc |
| Harvoni |
US7964580 (Pediatric) | NA | Sep 26, 2029 | Gilead Sciences Inc |
| Harvoni | US8088368 | Antiviral compounds | May 12, 2030 | Gilead Sciences Inc |
| Harvoni |
US8088368 (Pediatric) | Antiviral compounds | Nov 12, 2030 | Gilead Sciences Inc |
| Harvoni | US8273341 | Antiviral compounds | May 12, 2030 | Gilead Sciences Inc |
| Harvoni |
US8273341 (Pediatric) | Antiviral compounds | Nov 12, 2030 | Gilead Sciences Inc |
| Harvoni | US8334270 | NA | Mar 21, 2028 | Gilead Sciences Inc |
| Harvoni |
US8334270 (Pediatric) | NA | Sep 21, 2028 | Gilead Sciences Inc |
| Harvoni | US8580765 | NA | Mar 21, 2028 | Gilead Sciences Inc |
| Harvoni |
US8580765 (Pediatric) | NA | Sep 21, 2028 | Gilead Sciences Inc |
| Harvoni | US8618076 | Nucleoside phosphoramidates | Dec 11, 2030 | Gilead Sciences Inc |
| Harvoni |
US8618076 (Pediatric) | Nucleoside phosphoramidates | Jun 11, 2031 | Gilead Sciences Inc |
| Harvoni | US8633309 | Nucleoside phosphoramidates | Mar 26, 2029 | Gilead Sciences Inc |
| Harvoni |
US8633309 (Pediatric) | Nucleoside phosphoramidates | Sep 26, 2029 | Gilead Sciences Inc |
| Harvoni | US8735372 | NA | Mar 21, 2028 | Gilead Sciences Inc |
| Harvoni |
US8735372 (Pediatric) | NA | Sep 21, 2028 | Gilead Sciences Inc |
| Harvoni | US8822430 | Antiviral compounds | May 12, 2030 | Gilead Sciences Inc |
| Harvoni |
US8822430 (Pediatric) | Antiviral compounds | Nov 12, 2030 | Gilead Sciences Inc |
| Harvoni | US8841278 | Antiviral compounds | May 12, 2030 | Gilead Sciences Inc |
| Harvoni |
US8841278 (Pediatric) | Antiviral compounds | Nov 12, 2030 | Gilead Sciences Inc |
| Harvoni | US8889159 | Compositions and methods for treating hepatitis C virus | Mar 26, 2029 | Gilead Sciences Inc |
| Harvoni |
US8889159 (Pediatric) | Compositions and methods for treating hepatitis C virus | Sep 26, 2029 | Gilead Sciences Inc |
| Harvoni | US9085573 | NA | Mar 21, 2028 | Gilead Sciences Inc |
| Harvoni |
US9085573 (Pediatric) | NA | Sep 21, 2028 | Gilead Sciences Inc |
| Harvoni | US9284342 | Nucleoside phosphoramidates | Sep 13, 2030 | Gilead Sciences Inc |
| Harvoni |
US9284342 (Pediatric) | Nucleoside phosphoramidates | Mar 13, 2031 | Gilead Sciences Inc |
| Harvoni | US9393256 | Methods for treating HCV | Sep 14, 2032 | Gilead Sciences Inc |
| Harvoni |
US9393256 (Pediatric) | Methods for treating HCV | Mar 14, 2033 | Gilead Sciences Inc |
| Harvoni | US9511056 | Antiviral compounds | May 12, 2030 | Gilead Sciences Inc |
| Harvoni |
US9511056 (Pediatric) | Antiviral compounds | Nov 12, 2030 | Gilead Sciences Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳